Bottom line
XLV vs JDOC: the short answer
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and JDOC (JPMorgan Healthcare Leaders ETF) share a meaningful slice of their top holdings — about 62% by weight.
XLV is cheaper at 0.08% vs 0.65% — a difference of $57 a year per $10,000 invested.
Over one year, JDOC returned +14.9% vs +14.5% for XLV.
Updated Nov 19, 2026
XLV vs JDOC side by side
| XLV | JDOC | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | SPDR (State Street) | J.P. Morgan |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.08% | 0.65% |
| Annual cost per $10k | $8 | $65 |
| 10-yr cost on $10k (prospectus) | $103 | $810 |
| Max front load | None | None |
| 12b-1 fee | 0.02% | — |
| 1-yr return | +14.5% | +14.9% |
| 5-yr return (annualized) | +8.1% | — |
| 10-yr return (annualized) | +9.8% | — |
| Best quarter | +14.5% | +11.3% |
| Worst quarter | −12.7% | −11.9% |
| Net assets (fund) | $40.6B | $9.1M |
| Number of holdings | 65 | 61 |
| Portfolio turnover | 2% | 92% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | XLV | JDOC | Difference |
|---|---|---|---|
| 2025 | +14.5% | +14.9% | −0.4% |
| 2024 | +2.5% | −0.6% | +3.1% |
Source: Fund prospectus bar charts
Holdings overlap
15 of XLV's top 25 holdings also appear in JDOC's top 25.
| Holding | XLV | JDOC |
|---|---|---|
| Eli Lilly & Co | 16.51% | 7.76% |
| Johnson & Johnson | 10.64% | 4.82% |
| AbbVie Inc | 7.74% | 7.85% |
| UnitedHealth Group Inc | 6.57% | 5.85% |
| Merck & Co Inc | 5.52% | 4.82% |
| Thermo Fisher Scientific Inc | 3.24% | 3.73% |
| Abbott Laboratories | 2.75% | 3.11% |
| Intuitive Surgical Inc | 2.45% | 1.93% |
| CVS Health Corp | 2.30% | 2.83% |
| Danaher Corp | 2.09% | 2.16% |
| Bristol-Myers Squibb Co | 2.05% | 3.57% |
| Stryker Corp | 1.89% | 2.23% |
| Regeneron Pharmaceuticals Inc | 1.08% | 1.60% |
| Cardinal Health Inc | 0.97% | 1.51% |
| Cencora Inc | 0.96% | 2.07% |
Source: SEC Form N-PORT
XLV top 10
- Eli Lilly & Co — 16.51%
- Johnson & Johnson — 10.64%
- AbbVie Inc — 7.74%
- UnitedHealth Group Inc — 6.57%
- Merck & Co Inc — 5.52%
- Amgen Inc — 3.40%
- Thermo Fisher Scientific Inc — 3.24%
- Abbott Laboratories — 2.75%
- Gilead Sciences Inc — 2.73%
- Intuitive Surgical Inc — 2.45%
JDOC top 10
- AbbVie, Inc. — 7.85%
- Eli Lilly & Co. — 7.76%
- UnitedHealth Group, Inc. — 5.85%
- Merck & Co., Inc. — 4.82%
- Johnson & Johnson — 4.82%
- AstraZeneca plc — 3.76%
- Thermo Fisher Scientific, Inc. — 3.73%
- Bristol-Myers Squibb Co. — 3.57%
- Abbott Laboratories — 3.11%
- CVS Health Corp. — 2.83%
FAQ
What is the difference between XLV and JDOC?
Which is cheaper, XLV or JDOC?
Should I own both XLV and JDOC?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.